WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
Intel Corporation relies on outsourcing revenue to support its business, while Wells Fargo & Company sees potential in AMD seizing market share.
HK Bull/Bear Outstanding Qty Ratio(71:29) | January 24th
US Stock Market Move | EquipmentShare.com(EQPT.US) Debuts on the US Stock Market with a First-Day Trading Increase of 32.9%
Intel Corporation relies on outsourcing revenue to support its business, while Wells Fargo & Company sees potential in AMD seizing market share.
HK Bull/Bear Outstanding Qty Ratio(71:29) | January 24th
US Stock Market Move | EquipmentShare.com(EQPT.US) Debuts on the US Stock Market with a First-Day Trading Increase of 32.9%
RECOMMEND
Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026
Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026
Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026
